{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:11:37Z","timestamp":1776273097181,"version":"3.50.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.hoc.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T17:34:11Z","timestamp":1556645651000},"page":"639-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Luis M.","family":"Ju\u00e1rez-Salcedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2019.03.004_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2017"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.004_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2019.03.004_bib4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2019.03.004_bib5","doi-asserted-by":"crossref","unstructured":"Itchaki G, Dubeau T, Keezer A, et\u00a0al. Non-IgM secreting lymphoplasmacytic lymphoma - experience of a reference center for Waldenstrom macroglobulinemia. ASH Annual Meeting Abstracts. San Diego, December 2018: 2886.","DOI":"10.1182\/blood-2018-99-114254"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.004_bib6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/ajcp\/aqw072","article-title":"Lymphoplasmacytic lymphoma with a non-IgM paraprotein shows clinical and pathologic heterogeneity and may harbor MYD88 L265P mutations","volume":"145","author":"King","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.004_bib7","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A\u00a0mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom macroglobulinaemia: a Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.004_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.004_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.hoc.2019.03.004_bib11","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2019.03.004_bib12","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"123","author":"Castillo","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2019.03.004_bib13","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.hoc.2019.03.004_bib15","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2019.03.004_bib16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.hoc.2019.03.004_bib17","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2019.03.004_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2019.03.004_bib19","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in waldenstrom macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9873","key":"10.1016\/j.hoc.2019.03.004_bib20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.004_bib21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3816\/CLM.2002.n.022","article-title":"Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia","volume":"3","author":"Dimopoulos","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdi022","article-title":"Extended rituximab therapy in Waldenstrom's macroglobulinemia","volume":"16","author":"Treon","year":"2005","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.004_bib24","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2019.03.004_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2019.03.004_bib26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/bjh.13794","article-title":"Rituximab intolerance in patients with Waldenstrom macroglobulinaemia","volume":"174","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.hoc.2019.03.004_bib27","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.004_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.hoc.2019.03.004_bib29","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2019.03.004_bib30","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2019.03.004_bib31","unstructured":"Owen R, McCarthy H, Rule S, et\u00a0al. Acalabrutinib in patients with Waldenstr\u00f6m macroglobulinemia. EHA abstract. Stockholm, June 2018: S853."},{"key":"10.1016\/j.hoc.2019.03.004_bib32","unstructured":"Trotman J, Tam CS, Marlton P, et\u00a0al. Improved depth of response with increased follow-up for patients (PTS) with Waldenstr\u00f6m macroglobulinemia (WM) treated with Bruton\u2019s tyrosine kinase (BTK) inhibitor zanubrutinib. EHA abstract. Stockholm,\u00a0June 2018. PS1186."},{"key":"10.1016\/j.hoc.2019.03.004_bib33","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Gustine J, Meid K, et\u00a0al. Prospective phase ii study of venetoclax (VEN) in patients (PTS) with previously treated Waldenstrom macroglobulinemia (WM). EHA abstract. Stockholm, June 2018: S854.","DOI":"10.1182\/blood-2018-99-112325"},{"issue":"20","key":"10.1016\/j.hoc.2019.03.004_bib34","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2019.03.004_bib36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0929-8266(99)00080-4","article-title":"Endosonography in gastric lymphoma and large gastric folds","volume":"11","author":"Caletti","year":"2000","journal-title":"Eur J Ultrasound"},{"issue":"9","key":"10.1016\/j.hoc.2019.03.004_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN guidelines insights: Non-Hodgkin's lymphomas, version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.004_bib39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdl388","article-title":"Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT","volume":"18","author":"Arcaini","year":"2007","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2019.03.004_bib40","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1158\/1078-0432.CCR-04-0803","article-title":"Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma","volume":"10","author":"Wohrer","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2152","article-title":"Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis","volume":"33","author":"Treglia","year":"2015","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2019.03.004_bib42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/oxfordjournals.annonc.a058869","article-title":"Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma","volume":"5","author":"Rohatiner","year":"1994","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2019.03.004_bib43","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/01.pas.0000213275.60962.2a","article-title":"The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America","volume":"30","author":"Remstein","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"18","key":"10.1016\/j.hoc.2019.03.004_bib44","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1200\/JCO.2001.19.18.3861","article-title":"Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01\/92","volume":"19","author":"Koch","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2019.03.004_bib45","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1158\/1078-0432.CCR-14-0496","article-title":"Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas","volume":"20","author":"Zucca","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2019.03.004_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/asheducation-2013.1.109","article-title":"Helicobacter pylori and mucosa-associated lymphoid tissue: what's new","volume":"2013","author":"Kuo","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.hoc.2019.03.004_bib47","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2005-09-3679","article-title":"Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation","volume":"107","author":"Suarez","year":"2006","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.hoc.2019.03.004_bib48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jncimonographs\/lgu011","article-title":"Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Bracci","year":"2014","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2019.03.004_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.beha.2016.07.006","article-title":"Marginal zone lymphoma: associated autoimmunity and auto-immune disorders","volume":"30","author":"Teixeira Mendes","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.hoc.2019.03.004_bib50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/asheducation-2008.1.359","article-title":"Marginal zone lymphomas: management of nodal, splenic, and MALT NHL","volume":"1","author":"Kahl","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.004_bib51","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm","year":"1999","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.004_bib52","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2009-08-236265","article-title":"The t(14;18)(q32;q21)\/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma","volume":"115","author":"Murga Penas","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2019.03.004_bib53","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.leu.2403644","article-title":"T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma","volume":"19","author":"Streubel","year":"2005","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2019.03.004_bib54","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A\u00a0MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.004_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2009.07.017","article-title":"Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma","volume":"8","author":"Zullo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.004_bib56","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2015.01.040","article-title":"Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent","volume":"92","author":"Teckie","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.hoc.2019.03.004_bib58","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2019.03.004_bib59","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2019.03.004_bib60","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.004_bib61","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402","volume":"173","author":"Williams","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2019.03.004_bib62","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10428194.2012.729832","article-title":"Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study","volume":"54","author":"Levy","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.hoc.2019.03.004_bib63","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.004_bib64","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.15454","article-title":"High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO","volume":"182","author":"Avivi","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdn563","article-title":"Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients","volume":"20","author":"Boveri","year":"2009","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.004_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/10245332.2017.1279842","article-title":"Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era","volume":"22","author":"Starr","year":"2017","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.004_bib68","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/jcp.2010.076810","article-title":"Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas","volume":"63","author":"Chuang","year":"2010","journal-title":"J\u00a0Clin Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.11893","article-title":"Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles","volume":"100","author":"Arcaini","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2019.03.004_bib70","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2011.054080","article-title":"BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.004_bib71","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","author":"Martinez","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2019.03.004_bib72","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2019.03.004_bib73","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib74","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.004_bib75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2019.03.004_bib76","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.004_bib77","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalban","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib79","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","author":"Olszewski","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib80","doi-asserted-by":"crossref","first-page":"e2016030","DOI":"10.4084\/mjhid.2016.030","article-title":"Bendamustine and rituximab, as first line treatment, in intermediate, high risk splenic marginal zone lymphomas of elderly patients","volume":"8","author":"Castelli","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.004_bib81","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2019.03.004_bib82","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas","volume":"18","author":"Kelaidi","year":"2004","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.hoc.2019.03.004_bib83","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0609.2009.01301.x","article-title":"Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease","volume":"83","author":"Arcaini","year":"2009","journal-title":"Eur J Haematol"},{"issue":"17","key":"10.1016\/j.hoc.2019.03.004_bib85","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2019.03.004_bib86","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2019.03.004_bib87","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.004_bib88","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.27704","article-title":"Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients","volume":"119","author":"Heilgeist","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A\u00a0phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.004_bib90","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A\u00a0phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.004_bib91","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"35","key":"10.1016\/j.hoc.2019.03.004_bib92","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2019.03.004_bib93","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory Non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:10:53Z","timestamp":1760184653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858819300371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0889858819300371"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2019.03.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}